Synairgen have published a press release today announcing the data from their phase II trial of inhaled interferon beta (IFN-beta) in COVID-19 patients.
Dr Penny Ward, Faculty of Pharmaceutical Medicine, Visiting Professor in Pharmaceutical Medicine, Kings College London, said:
“It’s tough doing community trials in viral respiratory illness and all too easy to make a potentially great drug look ineffective, as I know only too well! The company have conducted a small study including older patients most of whom seem to have had pretty mild illness. However the fact that the two subjects hospitalized were both in the placebo group suggests that a larger trial might be able to demonstrate some protection from disease deterioration, hospitalisation and death if treatment is started promptly.